抗SSTR放射性配体治疗神经内分泌前列腺癌可行性的系统综述:影像与治疗研究
该系统综述纳入41项研究(4项前瞻性队列和37项病例报告/系列),评估SSTR靶向成像与SSTR导向放射性配体治疗在神经内分泌前列腺癌(NEPC)中的临床证据。患者层面报告中SSTR成像阳性率为76.3%(61/80),但队列研究显示仅少数患者有SSTR摄取且转移部位间存在异质性。9篇报告中的10例患者接受了SSTR导向PRRT(多为177Lu-DOTATATE),常描述症状获益及影像/生物标志物改善,但毒性报告有限。
要点
- NEPC中SSTR表达呈异质性,SSTR成像可用于表型分型和治疗选择。
- 患者层面报告中SSTR成像阳性率为76.3%(61/80例)。
- SSTR导向PRRT在少数患者中显示症状和影像/生物标志物改善,毒性报告有限。
核心结论
- NEPC中SSTR表达具有异质性,SSTR成像可支持表型分型和SSTR导向治疗的患者选择(包括PSMA低表达病变),但需前瞻性验证和标准化报告。
研究设计与样本
- 系统综述遵循PRISMA指南检索PubMed、Scopus和Web of Science(2025年9月14日),两名评价者筛选文献并提取数据,采用Joanna Briggs Institute工具评估偏倚风险,描述性综合。
- 共纳入41项研究,包括4项前瞻性队列和37项病例报告或系列。
主要发现
- 队列研究使用111In基SSTR闪烁显像(3项队列)或68Ga-DOTATATE PET/CT(1项队列),报告少数患者有SSTR摄取且转移部位间存在异质性。
- 患者层面报告中SSTR成像阳性率为76.3%(61/80例)。
- 常用示踪剂包括68Ga-DOTATATE(27/80)、68Ga-DOTANOC(17/80)、111In-octreotide或111In-pentetreotide(14/80)和18F-AlF-NOTA-octreotide(10/80)。
- 27例有PSMA成像数据,其中14例PSMA阴性者中11例存在SSTR摄取。
- 9篇报告中的10例患者接受了SSTR导向PRRT(最常用177Lu-DOTATATE),常描述症状获益及影像和/或生物标志物改善,毒性报告有限。
临床怎么用
- 对于NEPC患者,可考虑SSTR成像进行表型分型,尤其在PSMA低表达或阴性病变中评估SSTR导向治疗的可行性。
局限性
- 多数证据来自病例报告或系列,仅4项前瞻性队列,且SSTR摄取异质性大,毒性报告有限,需前瞻性验证和标准化报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To review clinical evidence on somatostatin receptor (SSTR) targeted imaging and SSTR directed radioligand therapy in neuroendocrine prostate cancer (NEPC). METHODS: A PRISMA guided search of PubMed, Scopus, and Web of Science was performed on September 14, 2025. Two reviewers screened studies and extracted data. Risk of bias was appraised using Joanna Briggs Institute tools. Synthesis was descriptive. RESULTS: Of 1937 records, 41 studies were included (4 prospective cohorts and 37 case reports or series). Case reports or series reported 80 patients with SSTR imaging. Cohort studies used 111In based SSTR scintigraphy (three cohorts) or 68Ga-DOTATATE PET/CT (one cohort) and reported SSTR uptake in a minority of patients with heterogeneity across metastatic sites. In patient level reports, SSTR imaging was positive in 61/80 cases (76.3%). Common tracers were 68Ga-DOTATATE (27/80), 68Ga-DOTANOC (17/80), 111In-octreotide or 111In-pentetreotide (14/80), and 18F-AlF-NOTA-octreotide (10/80). PSMA imaging was available in 27 cases; SSTR uptake was present in 11/14 PSMA negative cases. Ten patients in nine reports received SSTR directed PRRT, most often 177Lu-DOTATATE, with symptom benefit and imaging and/or biomarker improvement frequently described; toxicity reporting was limited. CONCLUSION: SSTR expression in NEPC is heterogeneous. SSTR imaging can support phenotyping and selection for SSTR directed therapy in selected patients, including PSMA low disease, but prospective validation with standardized reporting is needed.
引用
- Valizadeh P, Jannatdoust P, Shahgholianghahfarokhi M, et al. Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies. Semin Nucl Med. 2026. PMID: 42264967. doi:10.1053/j.semnuclmed.2026.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。